This model proposes that angiotensin and bradykinin receptor signaling can amplify inflammation by increasing ADAM17, which then reduces ACE2 and increases pro-inflammatory mediators.
First-pass extracted concept
Integrated angiotensin-bradykinin inflammatory feedback model
Aliases
RAS-bradykinin feedback model
Extracted Explainers
What the tool is doing
What problem it solves
Evidence Snippets
the angiotensin-bradykinin system is characterized by a powerful positive feedback loop that enhances inflammation through the Angiotensin and Bradykinin receptors that upregulate ADAM17, which in turn downregulates ACE2 and upregulates TNF- α and the pro-inflammatory receptor of the cytokine interleukin 6 (IL6).
Supporting Sources
Linked Claims
Lower COVID-19 severity in children despite lower ACE2 expression may be consistent with higher expression of ATR2 and the anti-inflammatory arm of the renin-angiotensin system at young age.
Failure of ACE2 to reverse the pro-inflammatory angiotensin-bradykinin state, possibly induced by SARS-CoV-2-mediated ACE2 degradation, may underlie severe COVID-19 and post-infection manifestations including MIS-C.
Age-associated increase in TACE/ADAM17 is proposed to drive ACE2 shedding from the cell membrane to serum, causing ACE2 cell protein to decline earlier and more steeply than ACE2 mRNA.
The angiotensin-bradykinin system contains a positive feedback loop in which angiotensin and bradykinin receptors upregulate ADAM17, which downregulates ACE2 and upregulates TNF-alpha and the pro-inflammatory IL6 receptor.